Trump administration pushing new drug spending cap
Axios– November 24, 2019
The Trump administration is pushing for a monthly cap on what seniors pay out-of-pocket for drugs through Medicare’s pharmacy benefit to be added to a bipartisan drug pricing bill in the Senate, a senior administration official told Axios’ Caitlin Owens and me.
The big picture: The cost of prescription drugs is still a top priority of the administration, even amidst all of the impeachment furor — and the president could very much use a big win on the subject heading into the 2020 election.
- Most of the administration’s major drug pricing policies have been tabled, are tied up in the courts or have yet to be implemented.
Between the lines: One unexpected side effect of impeachment is that it has dragged drug prices to the front of Trump’s mind again, the official said.
- Trump has been talking and meeting frequently with Republican lawmakers as part of his impeachment defense strategy.
- But, the official said, after the members discuss impeachment for a brief while with the president they usually pivot quickly and use their time with Trump to push their priorities.
- For many of these members of Congress, lowering drug prices is one of the most urgent demands they hear from their constituents. They want to be able to run on this issue in 2020 and they’re urging Trump to lean on Senate Republicans to pass a bill.
- Trump would not support Nancy Pelosi’s bill, so the only chance is the bill sponsored by Sens. Chuck Grassley (R-Iowa) and Ron Wyden (D-Ore.), the official said.
Details: The Grassley-Wyden bill currently caps enrollee cost-sharing in Part D at $3,100 a year beginning in 2022. The official said the administration is working with members to spread that cap out on a monthly basis.
- “Some seniors may max out in January, and that’s a big hit. And rather than have them spend that [on a] credit card and be in debt for 12 months or even longer … they could stagger that, and it would be a great benefit for them,” the official said.
- Grassley hinted at these changes last week, saying that the updated version of the bill “will improve the out-of-pocket cap by giving seniors and Americans with disabilities more flexibility when it comes to upfront costs.”
Recent Posts
-
LTC pharmacies said this would happen. New data says they were right.
By Donna Shryer // Published July 18, 2026 in McKnight’s Long-Term Care News Long-term care pharmacies predicted a steep reimbursement hit from the Inflation Reduction Act’s Medicare drug pricing changes. Now they say they have the data confirming it. A new analysis of member financial data shows reimbursement for drugs subject to the law’s negotiated […]
-
New Analysis Confirms Drug Pricing Changes Hurt LTC Pharmacies, Reinforces Need for Sustainable Payment Reform
Washington, D.C. (July 16, 2026)— A new analysis of member provided financial data confirms what the Senior Care Pharmacy Coalition (SCPC) has warned: the Inflation Reduction Act’s (IRA) Medicare drug pricing provisions that went into effect in 2026 have significantly reduced reimbursement for long-term care (LTC) pharmacies, threatening their financial sustainability and the benefits of […]
-
LTC Pharmacies Double Down On Call For PBM Contract Negotiation Reform
Lauren Brensel // Inside Health Policy – July 23, 2026 A group representing long-term care pharmacies is reminding policymakers of the negative impacts that result from problematic contract negotiations with pharmacy benefit managers, asking CMS to help alleviate pharmacies’ disputes with the three largest PBMs by embracing a series of reforms. LTC pharmacy services like […]
Stay Connected
Get the latest news and updates on issues impacting the long-term care pharmacy community.